Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Targeted therapy and disease monitoring in CNTRL-FGFR1-driven leukaemia.

Brown LM, Bartolo RC, Davidson NM, Schmidt B, Brooks I, Challis J, Petrovic V, Khuong-Quang DA, Mechinaud F, Khaw SL, Majewski IJ, Oshlack A, Ekert PG.

Pediatr Blood Cancer. 2019 Jun 28:e27897. doi: 10.1002/pbc.27897. [Epub ahead of print]

PMID:
31250523
2.

Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations.

Birkinshaw RW, Gong JN, Luo CS, Lio D, White CA, Anderson MA, Blombery P, Lessene G, Majewski IJ, Thijssen R, Roberts AW, Huang DCS, Colman PM, Czabotar PE.

Nat Commun. 2019 Jun 3;10(1):2385. doi: 10.1038/s41467-019-10363-1.

3.

On fitness: how do mutations shape the biology of cancer?

Majewski IJ.

Biochem Soc Trans. 2019 Apr 30;47(2):559-569. doi: 10.1042/BST20180224. Epub 2019 Mar 8. Review.

PMID:
30850423
4.

Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia.

Blombery P, Anderson MA, Gong JN, Thijssen R, Birkinshaw RW, Thompson ER, Teh CE, Nguyen T, Xu Z, Flensburg C, Lew TE, Majewski IJ, Gray DHD, Westerman DA, Tam CS, Seymour JF, Czabotar PE, Huang DCS, Roberts AW.

Cancer Discov. 2019 Mar;9(3):342-353. doi: 10.1158/2159-8290.CD-18-1119. Epub 2018 Dec 4.

PMID:
30514704
5.

MBD4 guards against methylation damage and germ line deficiency predisposes to clonal hematopoiesis and early-onset AML.

Sanders MA, Chew E, Flensburg C, Zeilemaker A, Miller SE, Al Hinai AS, Bajel A, Luiken B, Rijken M, Mclennan T, Hoogenboezem RM, Kavelaars FG, Fröhling S, Blewitt ME, Bindels EM, Alexander WS, Löwenberg B, Roberts AW, Valk PJM, Majewski IJ.

Blood. 2018 Oct 4;132(14):1526-1534. doi: 10.1182/blood-2018-05-852566. Epub 2018 Jul 26.

6.

Clinker: visualizing fusion genes detected in RNA-seq data.

Schmidt BM, Davidson NM, Hawkins ADK, Bartolo R, Majewski IJ, Ekert PG, Oshlack A.

Gigascience. 2018 Jul 1;7(7). doi: 10.1093/gigascience/giy079.

7.

Integrative Modeling Identifies Key Determinants of Inhibitor Sensitivity in Breast Cancer Cell Lines.

Jastrzebski K, Thijssen B, Kluin RJC, de Lint K, Majewski IJ, Beijersbergen RL, Wessels LFA.

Cancer Res. 2018 Aug 1;78(15):4396-4410. doi: 10.1158/0008-5472.CAN-17-2698. Epub 2018 May 29.

PMID:
29844118
8.

BAK/BAX-Mediated Apoptosis Is a Myc-Induced Roadblock to Reprogramming.

Kim EJY, Anko ML, Flensberg C, Majewski IJ, Geng FS, Firas J, Huang DCS, van Delft MF, Heath JK.

Stem Cell Reports. 2018 Feb 13;10(2):331-338. doi: 10.1016/j.stemcr.2017.12.019. Epub 2018 Jan 18.

9.

The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting.

Severson TM, Wolf DM, Yau C, Peeters J, Wehkam D, Schouten PC, Chin SF, Majewski IJ, Michaut M, Bosma A, Pereira B, Bismeijer T, Wessels L, Caldas C, Bernards R, Simon IM, Glas AM, Linn S, van 't Veer L.

Breast Cancer Res. 2017 Aug 25;19(1):99. doi: 10.1186/s13058-017-0861-2.

10.

ROBUST HYPERPARAMETER ESTIMATION PROTECTS AGAINST HYPERVARIABLE GENES AND IMPROVES POWER TO DETECT DIFFERENTIAL EXPRESSION.

Phipson B, Lee S, Majewski IJ, Alexander WS, Smyth GK.

Ann Appl Stat. 2016 Jun;10(2):946-963. doi: 10.1214/16-AOAS920. Epub 2016 Jul 22.

11.

A non-canonical function of Ezh2 preserves immune homeostasis.

Vasanthakumar A, Xu D, Lun AT, Kueh AJ, van Gisbergen KP, Iannarella N, Li X, Yu L, Wang D, Williams BR, Lee SC, Majewski IJ, Godfrey DI, Smyth GK, Alexander WS, Herold MJ, Kallies A, Nutt SL, Allan RS.

EMBO Rep. 2017 Apr;18(4):619-631. doi: 10.15252/embr.201643237. Epub 2017 Feb 21.

12.

The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism.

Anderson MA, Deng J, Seymour JF, Tam C, Kim SY, Fein J, Yu L, Brown JR, Westerman D, Si EG, Majewski IJ, Segal D, Heitner Enschede SL, Huang DC, Davids MS, Letai A, Roberts AW.

Blood. 2016 Jun 23;127(25):3215-24. doi: 10.1182/blood-2016-01-688796. Epub 2016 Apr 11.

13.

Polycomb repressive complex 2 component Suz12 is required for hematopoietic stem cell function and lymphopoiesis.

Lee SC, Miller S, Hyland C, Kauppi M, Lebois M, Di Rago L, Metcalf D, Kinkel SA, Josefsson EC, Blewitt ME, Majewski IJ, Alexander WS.

Blood. 2015 Jul 9;126(2):167-75. doi: 10.1182/blood-2014-12-615898. Epub 2015 Jun 2.

14.

JAFFA: High sensitivity transcriptome-focused fusion gene detection.

Davidson NM, Majewski IJ, Oshlack A.

Genome Med. 2015 May 11;7(1):43. doi: 10.1186/s13073-015-0167-x. eCollection 2015.

15.

Jarid2 regulates hematopoietic stem cell function by acting with polycomb repressive complex 2.

Kinkel SA, Galeev R, Flensburg C, Keniry A, Breslin K, Gilan O, Lee S, Liu J, Chen K, Gearing LJ, Moore DL, Alexander WS, Dawson M, Majewski IJ, Oshlack A, Larsson J, Blewitt ME.

Blood. 2015 Mar 19;125(12):1890-900. doi: 10.1182/blood-2014-10-603969. Epub 2015 Feb 2.

16.

PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer.

Majewski IJ, Nuciforo P, Mittempergher L, Bosma AJ, Eidtmann H, Holmes E, Sotiriou C, Fumagalli D, Jimenez J, Aura C, Prudkin L, Díaz-Delgado MC, de la Peña L, Loi S, Ellis C, Schultz N, de Azambuja E, Harbeck N, Piccart-Gebhart M, Bernards R, Baselga J.

J Clin Oncol. 2015 Apr 20;33(12):1334-9. doi: 10.1200/JCO.2014.55.2158. Epub 2015 Jan 5.

17.

The pseudokinase MLKL mediates necroptosis via a molecular switch mechanism.

Murphy JM, Czabotar PE, Hildebrand JM, Lucet IS, Zhang JG, Alvarez-Diaz S, Lewis R, Lalaoui N, Metcalf D, Webb AI, Young SN, Varghese LN, Tannahill GM, Hatchell EC, Majewski IJ, Okamoto T, Dobson RC, Hilton DJ, Babon JJ, Nicola NA, Strasser A, Silke J, Alexander WS.

Immunity. 2013 Sep 19;39(3):443-53. doi: 10.1016/j.immuni.2013.06.018. Epub 2013 Sep 5.

18.

Polycomb repressive complex 2 (PRC2) suppresses Eμ-myc lymphoma.

Lee SC, Phipson B, Hyland CD, Leong HS, Allan RS, Lun A, Hilton DJ, Nutt SL, Blewitt ME, Smyth GK, Alexander WS, Majewski IJ.

Blood. 2013 Oct 10;122(15):2654-63. doi: 10.1182/blood-2013-02-484055. Epub 2013 Aug 27.

19.

Identification of recurrent FGFR3 fusion genes in lung cancer through kinome-centred RNA sequencing.

Majewski IJ, Mittempergher L, Davidson NM, Bosma A, Willems SM, Horlings HM, de Rink I, Greger L, Hooijer GK, Peters D, Nederlof PM, Hofland I, de Jong J, Wesseling J, Kluin RJ, Brugman W, Kerkhoven R, Nieboer F, Roepman P, Broeks A, Muley TR, Jassem J, Niklinski J, van Zandwijk N, Brazma A, Oshlack A, van den Heuvel M, Bernards R.

J Pathol. 2013 Jul;230(3):270-6. doi: 10.1002/path.4209.

PMID:
23661334
20.

Epigenetic regulator Smchd1 functions as a tumor suppressor.

Leong HS, Chen K, Hu Y, Lee S, Corbin J, Pakusch M, Murphy JM, Majewski IJ, Smyth GK, Alexander WS, Hilton DJ, Blewitt ME.

Cancer Res. 2013 Mar 1;73(5):1591-9. doi: 10.1158/0008-5472.CAN-12-3019. Epub 2012 Dec 26.

21.

An α-E-catenin (CTNNA1) mutation in hereditary diffuse gastric cancer.

Majewski IJ, Kluijt I, Cats A, Scerri TS, de Jong D, Kluin RJ, Hansford S, Hogervorst FB, Bosma AJ, Hofland I, Winter M, Huntsman D, Jonkers J, Bahlo M, Bernards R.

J Pathol. 2013 Mar;229(4):621-9. doi: 10.1002/path.4152.

PMID:
23208944
22.

A regression model for estimating DNA copy number applied to capture sequencing data.

Rigaill GJ, Cadot S, Kluin RJ, Xue Z, Bernards R, Majewski IJ, Wessels LF.

Bioinformatics. 2012 Sep 15;28(18):2357-65. doi: 10.1093/bioinformatics/bts448. Epub 2012 Jul 13.

PMID:
22796958
23.

ChIP-seq analysis reveals distinct H3K27me3 profiles that correlate with transcriptional activity.

Young MD, Willson TA, Wakefield MJ, Trounson E, Hilton DJ, Blewitt ME, Oshlack A, Majewski IJ.

Nucleic Acids Res. 2011 Sep 1;39(17):7415-27. doi: 10.1093/nar/gkr416. Epub 2011 Jun 7.

24.

Taming the dragon: genomic biomarkers to individualize the treatment of cancer.

Majewski IJ, Bernards R.

Nat Med. 2011 Mar;17(3):304-12. doi: 10.1038/nm.2311.

PMID:
21386834
25.

Opposing roles of polycomb repressive complexes in hematopoietic stem and progenitor cells.

Majewski IJ, Ritchie ME, Phipson B, Corbin J, Pakusch M, Ebert A, Busslinger M, Koseki H, Hu Y, Smyth GK, Alexander WS, Hilton DJ, Blewitt ME.

Blood. 2010 Aug 5;116(5):731-9. doi: 10.1182/blood-2009-12-260760. Epub 2010 May 5.

26.

Hematopoietic defects in the Ts1Cje mouse model of Down syndrome.

Carmichael CL, Majewski IJ, Alexander WS, Metcalf D, Hilton DJ, Hewitt CA, Scott HS.

Blood. 2009 Feb 26;113(9):1929-37. doi: 10.1182/blood-2008-06-161422. Epub 2008 Dec 24.

27.

Polycomb repressive complex 2 (PRC2) restricts hematopoietic stem cell activity.

Majewski IJ, Blewitt ME, de Graaf CA, McManus EJ, Bahlo M, Hilton AA, Hyland CD, Smyth GK, Corbin JE, Metcalf D, Alexander WS, Hilton DJ.

PLoS Biol. 2008 Apr 15;6(4):e93. doi: 10.1371/journal.pbio.0060093.

28.

Hls5 regulated erythroid differentiation by modulating GATA-1 activity.

Endersby R, Majewski IJ, Winteringham L, Beaumont JG, Samuels A, Scaife R, Lim E, Crossley M, Klinken SP, Lalonde JP.

Blood. 2008 Feb 15;111(4):1946-50. Epub 2007 Dec 6.

29.

A mutation in the translation initiation codon of Gata-1 disrupts megakaryocyte maturation and causes thrombocytopenia.

Majewski IJ, Metcalf D, Mielke LA, Krebs DL, Ellis S, Carpinelli MR, Mifsud S, Di Rago L, Corbin J, Nicola NA, Hilton DJ, Alexander WS.

Proc Natl Acad Sci U S A. 2006 Sep 19;103(38):14146-51. Epub 2006 Sep 11.

Supplemental Content

Loading ...
Support Center